Status:
RECRUITING
Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis
Lead Sponsor:
Shirley Ryan AbilityLab
Conditions:
Multiple Sclerosis
Multiple Sclerosis, Secondary Progressive
Eligibility:
All Genders
18-75 years
Brief Summary
The purpose of this study is to develop a measurement of walking quality, called Gait Deviation Index (GDI) for people with Multiple Sclerosis (MS).
Detailed Description
In rehabilitation in general, in order to track patients' progress and provide next steps, there is a need for easily obtainable, understandable, and objective measures of ability. Currently, there is...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosis of relapsing form of MS (including relapsing-remitting MS and secondary progressive MS)
- Able to ambulate overground
- Relapse free for at least 1 month
- Age ≥18 and ≤ 75 years
- Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening
- Exclusion criteria:
- \- Orthopedic injuries, fractures, surgeries or other conditions affecting locomotor function or weight bearing
Exclusion
Key Trial Info
Start Date :
July 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06516458
Start Date
July 1 2024
End Date
July 1 2026
Last Update
July 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shirley Ryan AbilityLab
Chicago, Illinois, United States, 60611